Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Colorectal Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 25 articles: HTML format

Single Articles

June 2025
1. HUANG YQ, Chen XB, Cui YF, Yang F, et al
   Enhanced risk stratification for stage II colorectal cancer using deep learning-based CT classifier and pathological markers to optimize adjuvant therapy decision.
   Ann Oncol. 2025 Jun 4:S0923-7534(25)00766-5. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
2. RIEDL JM, Fece de la Cruz F, Lin JJ, Parseghian C, et al
   Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors.
   Ann Oncol. 2025;36:682-692.
   PubMed     Abstract available
   
   
   May 2025
3. WILLIAMS H, Fokas E, Diefenhardt M, Lee C, et al
   Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials.
   Ann Oncol. 2025;36:543-547.
   PubMed     Abstract available
   
   
   February 2025
4. BARON D, Pace Loscos T, Schiappa R, Barbet N, et al
   A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial.
   Ann Oncol. 2025;36:208-215.
   PubMed     Abstract available
   
   
   January 2025
5. SELIGMANN JF, Morton D, Elliott F, Handley K, et al
   Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT Trial embedded phase II population.
   Ann Oncol. 2025 Jan 11:S0923-7534(25)00002-X. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   December 2024
6. MARTINEZ-CASTEDO B, Camblor DG, Martin-Arana J, Carbonell-Asins JA, et al
   Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.
   Ann Oncol. 2024 Dec 13:S0923-7534(24)04981-0. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
7. CANDIA L, Cervantes A, Martinelli E
   Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline.
   Ann Oncol. 2024 Dec 3:S0923-7534(24)04952-4. doi: 10.1016/j.annonc.2024.
   PubMed    
   
   
   
8. ANDRE T, Shiu KK, Kim TW, Jensen BV, et al
   Pembrolizumab Versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study.
   Ann Oncol. 2024 Dec 2:S0923-7534(24)04949-4. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
9. BEEHUAT TAN I, Lui R, Yan K, Lam R, et al
   Investigating the 'liquid-solid interface' in the comprehensive genomic profiling of metastatic colorectal cancer for guiding treatment-where do we draw the line?
   Ann Oncol. 2024;35:1067-1070.
   PubMed    
   
   
   November 2024
10. DE WILT JHW, van der Kruijssen DEW, Koopman M
    Reply to Letter to the Editor "Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4" by Guzel et al.
    Ann Oncol. 2024 Nov 4:S0923-7534(24)04052-3. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
11. KATAOKA K, Mori K, Nakamura Y, Watanabe J, et al
    Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
    Ann Oncol. 2024;35:1015-1025.
    PubMed     Abstract available
    
    
    
12. BERCZ A, Park BK, Pappou E, Nemirovsky D, et al
    Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy.
    Ann Oncol. 2024;35:1003-1014.
    PubMed     Abstract available
    
    
    October 2024
13. GUZEL HG, Ilhan Y, Onder AH
    Optimising Treatment Strategies in Metastatic Colorectal Cancer: Insights from CAIRO4.
    Ann Oncol. 2024 Oct 10:S0923-7534(24)04053-5. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
14. ROMESSER PB, Cercek A
    Optimizing Rectal Cancer Treatment: A Path Towards Personalization.
    Ann Oncol. 2024;35:831-835.
    PubMed    
    
    
    
15. CONROY T, Castan F, Etienne PL, Rio E, et al
    Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.
    Ann Oncol. 2024;35:873-881.
    PubMed     Abstract available
    
    
    
16. LIN ZY, Zhang P, Chi P, Xiao Y, et al
    Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.
    Ann Oncol. 2024;35:882-891.
    PubMed     Abstract available
    
    
    August 2024
17. CIARDIELLO D, Bielo LB, Napolitano S, Martinelli E, et al
    Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF(V600E) wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial.
    Ann Oncol. 2024 Aug 28:S0923-7534(24)03914-0. doi: 10.1016/j.annonc.2024.08.2334
    PubMed     Abstract available
    
    
    
18. ROS J, Matito J, Villacampa G, Comas R, et al
    Corrigendum to "Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments": [Annals of Oncology 34 (2023) 543-552].
    Ann Oncol. 2024 Aug 12:S0923-7534(23)00796-2. doi: 10.1016/j.annonc.2023.
    PubMed    
    
    
    July 2024
19. BIONDO S, Frago R, Kreisler E
    Primary tumor resection for asymptomatic colorectal cancer with unresectable metastasis: the end of the dilemma.
    Ann Oncol. 2024 Jul 3:S0923-7534(24)00767-1. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    
20. CECCHINI M, Sundar R
    Proofreading the way: immune checkpoint inhibitors in polymerase epsilon/polymerase delta (POLE/POLD1)-altered colorectal cancer.
    Ann Oncol. 2024;35:582-584.
    PubMed    
    
    
    June 2024
21. VAN DER KRUIJSSEN DEW, Elias SG, van de Ven PM, van Rooijen KL, et al
    Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.
    Ann Oncol. 2024 Jun 7:S0923-7534(24)00722-1. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    May 2024
22. AMBROSINI M, Rousseau B, Manca P, Artz O, et al
    Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
    Ann Oncol. 2024 May 3:S0923-7534(24)00104-2. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    
23. BRENNER H, Niedermaier T, Hoffmeister M
    Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms.
    Ann Oncol. 2024;35:476-477.
    PubMed    
    
    
    April 2024
24. KELSEN D, Ben-Aharon I, Gordon N
    Identifying Genetic Loci Associated with an Increased Risk for Early Onset Colorectal Cancer.
    Ann Oncol. 2024 Apr 3:S0923-7534(24)00106-6. doi: 10.1016/j.annonc.2024.
    PubMed    
    
    
    February 2024
25. LASKAR RS, Qu C, Huyghe JR, Harrison T, et al
    Genome-wide association study and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.
    Ann Oncol. 2024 Feb 24:S0923-7534(24)00058-9. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.